|
|
News Breaks | | | | November 11, 2012 | | 12:13 EDT |  | VRTX | Vertex announced data on on ALS-2200 are being presented at AASLD
Vertex Pharmaceuticals announced that data on ALS-2200, VX-135, an oral medicine Vertex is developing for the treatment of hepatitis C, are being presented for the first time at The Liver Meeting, the 63rd Annual Meeting of the American Association for the Study of Liver Diseases, AASLD. Data from viral kinetic study showed rapid reduction of HCV RNA with ALS-2200 (VX-135), Vertex’s oral nucleotide analogue in development for the treatment of hepatitis C. | |
|
News For VRTX From The Last 14 Days Check below for free stories on VRTX the last two weeks. |
|
|
| May 10, 2013 | | 14:02 EDT |  | VRTX | Vertex to benefit from Welsh government decision, says Wells Fargo
 Subscribe for More Information | |
|
|
|
|
|
|
